Therapies Beyond BCG: FDA-Approved and Emerging Options

According to the company, the MHRA approval represents the first marketing approval outside the US for NAI.

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

The data, collected as part of the phase 1/2 Duravelo-1 trial, showed an objective response rate of 65%.

“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.

Catch up on exclusive videos you may have missed from the first half of the year.

Here’s a look back at notable news between April and June 2025.